• Helix BioPharma appointed Markus Loeffler as chief medical officer as it shifts into a more execution-focused phase of clinical development.
• Loeffler will lead clinical strategy, including a planned Phase Ib/II study of L-DOS47 with pembrolizumab in first-line NSCLC.
• He will also guide LEUMUNA toward clinical development for leukemia relapse following allogeneic stem cell transplantation.
• Loeffler is a physician-scientist with more than 30 years in oncology drug development, including senior roles at Roche.
• He previously led the Phase III program for Lutathera, later approved for certain gastroenteropancreatic neuroendocrine tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Helix BioPharma Corp. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202608171715TNWSWRCACNPR_____1ArbFWK1P) on August 17, 2026, and is solely responsible for the information contained therein.